Literature DB >> 17349009

Translational mini-review series on type 1 diabetes: Systematic analysis of T cell epitopes in autoimmune diabetes.

T P Di Lorenzo1, M Peakman, B O Roep.   

Abstract

T cell epitopes represent the molecular code words through which the adaptive immune system communicates. In the context of a T cell-mediated autoimmune disease such as type 1 diabetes, CD4 and CD8 T cell recognition of islet autoantigenic epitopes is a key step in the autoimmune cascade. Epitope recognition takes place during the generation of tolerance, during its loss as the disease process is initiated, and during epitope spreading as islet cell damage is perpetuated. Epitope recognition is also a potentially critical element in therapeutic interventions such as antigen-specific immunotherapy. T cell epitope discovery, therefore, is an important component of type 1 diabetes research, in both human and murine models. With this in mind, in this review we present a comprehensive guide to epitopes that have been identified as T cell targets in autoimmune diabetes. Targets of both CD4 and CD8 T cells are listed for human type 1 diabetes, for humanized [human leucocyte antigen (HLA)-transgenic] mouse models, and for the major spontaneous disease model, the non-obese diabetic (NOD) mouse. Importantly, for each epitope we provide an analysis of the relative stringency with which it has been identified, including whether recognition is spontaneous or induced and whether there is evidence that the epitope is generated from the native protein by natural antigen processing. This analysis provides an important resource for investigating diabetes pathogenesis, for developing antigen-specific therapies, and for developing strategies for T cell monitoring during disease development and therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17349009      PMCID: PMC1868845          DOI: 10.1111/j.1365-2249.2006.03244.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  105 in total

Review 1.  Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?

Authors:  M Peakman; C M Dayan
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

2.  Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood.

Authors:  Jacqueline D Trudeau; Carolyn Kelly-Smith; C Bruce Verchere; John F Elliott; Jan P Dutz; Diane T Finegood; Pere Santamaria; Rusung Tan
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

3.  ICA69(null) nonobese diabetic mice develop diabetes, but resist disease acceleration by cyclophosphamide.

Authors:  Shawn Winer; Igor Astsaturov; Roger Gaedigk; Denise Hammond-McKibben; Marc Pilon; Aihua Song; Violetta Kubiak; Wolfram Karges; Enrico Arpaia; Colin McKerlie; Peter Zucker; Bhagirath Singh; H-Michael Dosch
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

4.  Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial.

Authors:  I Raz; D Elias; A Avron; M Tamir; M Metzger; I R Cohen
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

5.  Predominantly recognized proinsulin T helper cell epitopes in individuals with and without islet cell autoimmunity.

Authors:  Ivana Durinovic-Belló; Bernhard O Boehm; Anette-G Ziegler
Journal:  J Autoimmun       Date:  2002-02       Impact factor: 7.094

6.  Evidence that a peptide spanning the B-C junction of proinsulin is an early Autoantigen epitope in the pathogenesis of type 1 diabetes.

Authors:  W Chen; I Bergerot; J F Elliott; L C Harrison; N Abiru; G S Eisenbarth; T L Delovitch
Journal:  J Immunol       Date:  2001-11-01       Impact factor: 5.422

7.  Humoral and cellular immune responses to proinsulin in adults with newly diagnosed type 1 diabetes.

Authors:  Parth Narendran; Alistair J Williams; Kathryn Elsegood; Nicola J Leech; Colin M Dayan
Journal:  Diabetes Metab Res Rev       Date:  2003 Jan-Feb       Impact factor: 4.876

8.  Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects.

Authors:  Helena Reijonen; Erik J Novak; Sharon Kochik; Anne Heninger; Andrew W Liu; William W Kwok; Gerald T Nepom
Journal:  Diabetes       Date:  2002-05       Impact factor: 9.461

9.  T cell response to preproinsulin I and II in the nonobese diabetic mouse.

Authors:  Philippe Halbout; Jean-Paul Briand; Chantal Bécourt; Sylviane Muller; Christian Boitard
Journal:  J Immunol       Date:  2002-09-01       Impact factor: 5.422

10.  CD4(+) T cells from glutamic acid decarboxylase (GAD)65-specific T cell receptor transgenic mice are not diabetogenic and can delay diabetes transfer.

Authors:  Kristin V Tarbell; Mark Lee; Erik Ranheim; Cheng Chi Chao; Maija Sanna; Seon-Kyeong Kim; Peter Dickie; Luc Teyton; Mark Davis; Hugh McDevitt
Journal:  J Exp Med       Date:  2002-08-19       Impact factor: 14.307

View more
  137 in total

1.  Type 1 diabetes-associated HLA-DQ8 transdimer accommodates a unique peptide repertoire.

Authors:  Menno van Lummel; Peter A van Veelen; Arnaud Zaldumbide; Arnoud de Ru; George M C Janssen; Antonis K Moustakas; George K Papadopoulos; Jan W Drijfhout; Bart O Roep; Frits Koning
Journal:  J Biol Chem       Date:  2011-12-19       Impact factor: 5.157

Review 2.  Current approaches to measuring human islet-antigen specific T cell function in type 1 diabetes.

Authors:  S I Mannering; F S Wong; I Durinovic-Belló; B Brooks-Worrell; T I Tree; C M Cilio; N C Schloot; R Mallone
Journal:  Clin Exp Immunol       Date:  2010-09-15       Impact factor: 4.330

3.  Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading.

Authors:  Suchitra Prasad; Adam P Kohm; Jeffrey S McMahon; Xunrong Luo; Stephen D Miller
Journal:  J Autoimmun       Date:  2012-05-28       Impact factor: 7.094

Review 4.  The case for an autoimmune aetiology of type 1 diabetes.

Authors:  S I Mannering; V Pathiraja; T W H Kay
Journal:  Clin Exp Immunol       Date:  2015-10-21       Impact factor: 4.330

Review 5.  Viruses and cytotoxic T lymphocytes in type 1 diabetes.

Authors:  Ken T Coppieters; Matthias G von Herrath
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

Review 6.  Deciphering the Pathogenesis of Human Type 1 Diabetes (T1D) by Interrogating T Cells from the "Scene of the Crime".

Authors:  Sally C Kent; Stuart I Mannering; Aaron W Michels; Jenny Aurielle B Babon
Journal:  Curr Diab Rep       Date:  2017-09-02       Impact factor: 4.810

7.  Proinsulin C-peptide is an autoantigen in people with type 1 diabetes.

Authors:  Michelle So; Colleen M Elso; Eleonora Tresoldi; Miha Pakusch; Vimukthi Pathiraja; John M Wentworth; Leonard C Harrison; Balasubramanian Krishnamurthy; Helen E Thomas; Christine Rodda; Fergus J Cameron; Jacinta McMahon; Thomas W H Kay; Stuart I Mannering
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-01       Impact factor: 11.205

8.  Increased islet antigen-specific regulatory and effector CD4+ T cells in healthy individuals with the type 1 diabetes-protective haplotype.

Authors:  Xiaomin Wen; Junbao Yang; Eddie James; I-Ting Chow; Helena Reijonen; William W Kwok
Journal:  Sci Immunol       Date:  2020-02-14

9.  The A-chain of insulin is a hot-spot for CD4+ T cell epitopes in human type 1 diabetes.

Authors:  S I Mannering; S H Pang; N A Williamson; G Naselli; E C Reynolds; N M O'Brien-Simpson; A W Purcell; L C Harrison
Journal:  Clin Exp Immunol       Date:  2009-03-09       Impact factor: 4.330

10.  Evaluating the intrinsic cysteine redox-dependent states of the A-chain of human insulin using NMR spectroscopy, quantum chemical calculations, and mass spectrometry.

Authors:  Alok K Sharma; Yan Ling; Allison B Greer; David A Hafler; Sally C Kent; Yong Zhang; Alan C Rigby
Journal:  J Phys Chem B       Date:  2010-01-14       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.